A double-blind, placebo controlled, randomized, cross-over polysomnographic study of MK0928 [gaboxadol] 15 mg in adult patients with primary insomnia
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Merck & Co
- 23 Jan 2007 New trial record.